The Clinical Outcomes of a Nursing System for Hepatocellular Carcinoma Outpatients Undergoing Trans-Arterial Chemoembolization: A 10-year Retrospective Study
Article Sidebar
Main Article Content
Abstract
Abstract: This is a retrospective study aimed to evaluate the clinical outcomes of hepatocellular carcinoma (HCC) outpatients who received trans-arterial chemoembolization (TACE) at a university hospital in Southern Thailand. The sample consisted of 658 HCC outpatients, who received a total of 874 TACE times between 2012 and 2021. The tools used to record data were 1) a form to record complications after treatment, and 2) a form to record waiting times for accessing treatment. Data were analyzed using descriptive statistics. The results of the study showed that 32.95% of HCC outpatients who received TACE experienced complications, mostly common complications of post-embolization syndrome (23.56%). Serious but rare complications included liver function decline (1.26%), acute cholecystitis (0.23%), and renal function decline (0.11%). The average waiting time for accessing TACE was 57.20 days (standard deviation 12.23 days). It is concluded that the nursing system and treatment for HCC outpatients who received TACE are safe and effective in helping to reduce the waiting time for treatment. Therefore, a nursing system for HCC patients who receive TACE should be developed in which the procedure is performed and the patient allowed to go to home the same day to increase the quality of life for patients, reduce the waiting time for access treatment and help reduce the problem of a shortage of beds to accommodate patients in hospitals.
Downloads
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
References
Raoul JL, Forner A, Bolondi L, et al. Updated use of TACE for hepatocellular carcinoma treatment: How and when to use it based on clinical evidence. Cancer Treat Rev. 2019; 72: 28-36.doi: 10.1016/j.ctrv.2018.11.002.
Kong C, Zhao Z, Chen W, et al. Prediction of tumor response via a pretreatment MRI radiomics-based nomogram in HCC treated with TACE. Eur Radiol. 2021; 31(10): 7500-11. doi: 10.1007/s00330-021-07910-0.
Peng CW, Teng W, Lui KW, et al. Complete response at first transarterial chemoembolization predicts favorable outcome in hepatocellular carcinoma. Am J Cancer Res. 2021;11 (10):4956-65.
Gabutti A, Cascella T. How to radiologically assess and follow response after treatment of hepatocellular carcinoma. Oncology (Williston Park). 2021; 35(4): 199-204. doi: 10.46883/ONC.2021.3504.0199.
Chuangaroon A, Wongsaichue C, Linthong S, et al. The development of nursing service system for primary liver cancer patients receiving transarterial chemoembolization (TACE) at National Cancer Institute. J Depart Medical Services. 2020; 45(2): 184-90. Thai.
Songklanagarind Hospital. Medical Statistics Unit. hepatocellular carcinoma patient statistics 2012 to 2021. Songkhla: Hospital; 2022. Thai.
Songklanagarind Hospital. Department of Internal Medicine. Information on PCT internal medicine. Songkhla: Hospital; 2022. Thai.
Temthup S. Indicator report of advanced practice nurse. Nursing Service Division, Songklanagarind Hospital: Songkhla; 2022. Thai.
Hund HC, Frantz SK, Wu H, et al. Six-year evaluation of same-day discharge following conventional transarterial chemoembolization of hepatocellular carcinoma. J Vasc Interv Radiol. 2023; 34(3): 378-85. doi: 10.1016/j.jvir.2022.11.029.
Fritsche MR, Watchmaker JM, Lipnik AJ, et al. Outpatient transarterial chemoembolization of hepatocellular carcinoma: Review of a same-day discharge strategy. J Vasc Interv Radiol. 2018; 29(4): 550-5. doi: 10.1016/j.jvir.2017.11.018.
Lima M, Dutra S, Gomes FV, et al. Risk factors for the development of postembolization syndrome after transarterial chemoembolization for hepatocellular carcinoma treatment.Acta Med Port. 2018; 31(1): 22-9. doi: 10.20344/amp.8976.
He JJ, Yin XX, Wang T, et al. Factors influencing postembolization syndrome in patients with hepatocellular carcinoma undergoing first transcatheter arterial chemoembolization. J Cancer Res Ther. 2021; 17(3): 777-83. doi: 10.4103/jcrt.jcrt_132_21.
Byeol LH, Soo KM. Risk predictors of postembolization syndrome after transarterial chemoembolization by sex: A retrospective study. Korean J Adult Nursing. 2023; 35(4): 418-27. doi: 10.7475/kjan.2023.35.4.418.
Miyayama S, Matsui O. Superselective conventional transarterial chemoembolization for hepatocellular carcinoma: Rationale, technique, and outcome. J Vasc Interv Radiol. 2016; 27(9): 1269-78. doi: 10.1016/j.jvir.2016.04.014.
Roehlen N, Stoehr F, Müller L, et al. Prediction of postembolization syndrome after transarterial chemoembolization of hepatocellular carcinoma and its impact on prognosis. Hepatol Commun. 2023; 7(10): e0252. doi: 10.1097/HC9.0000000
Lee HN, Hyun D. Complications related to transarterial treatment of hepatocellular carcinoma: A comprehensive review. Korean J Radiol. 2023; 24(3): 204-23. doi: 10.3348/kjr.2022.0395.
Cho Y, Choi JW, Kwon H, et al. Transarterial chemoembolization for hepatocellular carcinoma: 2023 expert consensus-based practical recommendations of the Korean Liver Cancer Association. Clinical Molecular Hepatology. 2023; 29(3): 521-41. doi:
3350/cmh.2023.0202.
Thai Association for the Study of the Liver. Thailand guideline for management of hepatocellular carcinoma 2021. Bangkok: Association; 2021. Thai.
Temthup S, Nilmanat K, Udomvisatson R, et al. The effectiveness of a new clinical nursing practice guideline on level of back pain, bleeding, and hematoma formation in patients with hepatocellular carcinoma (HCC) who are receiving transcatheter arterial chemoembolization (TACE). The Southern College Network J Nursing Public Health. 2022; 9(2): 54-65. Thai.